Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris

ClinicalTrials.gov ID: NCT06733402

Public ClinicalTrials.gov record NCT06733402. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-group Study, Comparing Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A, Inc.) to Aklief® Cream (US REFERENCE LISTED DRUG), Aklief Cream (REFERENCE PRODUCT) and Each Active Treatment to a Placebo Control in the Treatment of Acne Vulgaris.

Study identification

NCT ID
NCT06733402
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Enrollment
1,000 participants

Conditions and interventions

Conditions

Interventions

  • Trifarotene Cream 0.005% Drug
  • AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG Drug
  • AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
12 Years to 40 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 19, 2024
Primary completion
Jun 19, 2024
Completion
Nov 8, 2024
Last update posted
Dec 12, 2024

2024

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Taro Pharmaceuticals USA Inc. Hawthorne New York 10532

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06733402, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 12, 2024 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06733402 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →